Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

610
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
610
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

579
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
579
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

1.5K
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.5K
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

1.2K
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
1.2K
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

1.5K
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
1.5K
Heart Failure I: Introduction01:27

Heart Failure I: Introduction

1.3K
Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
1.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Analysis of Circulating Long Non-Coding RNA in Prediabetes or Newly Diagnosed Type 2 Diabetes Subjects With or Without Heart Stress.

Diabetes/metabolism research and reviews·2026
Same author

Exercise Training and Cardiac Rehabilitation in Chronic Thromboembolic Pulmonary Hypertension.

Heart failure clinics·2026
Same author

Hospital-to-community care pathways for patients with heart failure, an inter-society consensus document.

European journal of internal medicine·2026
Same author

Continuous Versus Intermittent Loop Diuretics Step-by-Step Protocol in Acute Heart Failure (DIUR-AHF): A Propensity-Matched Analysis.

Journal of the American Heart Association·2026
Same author

Cardiac rehabilitation in overweight and obese patients: Challenges, strategies, and the role of emerging anti-obesity therapies.

Current problems in cardiology·2026
Same author

Prognostic Thresholds of Pulmonary Artery Pressure and Right Ventricular Function at Echocardiography in Heart Failure.

The American journal of cardiology·2026

Related Experiment Video

Updated: Apr 15, 2026

Implantation of the Syncardia Total Artificial Heart
16:11

Implantation of the Syncardia Total Artificial Heart

Published on: July 18, 2014

36.3K

Hormone replacement therapy in heart failure.

Michele Arcopinto1, Andrea Salzano, Jorgen Isgaard

  • 1aDepartment of Cardiac Surgery, IRCCS Policlinico San Donato Milanese, Milan bDepartment of Translational Medical Sciences, Federico II University cInterdisciplinary Research Centre in Biomedical Materials (CRIB), University of Naples, Naples, Italy dDepartment of Internal Medicine, Sahlgrenska Academy, University of Göthenborg, Göthenborg, Sweden *Jorgen Isgaard and Antonio Cittadini contributed equally to the writing of this article.

Current Opinion in Cardiology
|March 26, 2015
PubMed
Summary
This summary is machine-generated.

Hormone replacement therapy (HRT) may offer a novel approach to treating chronic heart failure (CHF) by addressing anabolic deficiencies. This could improve cardiac function and patient quality of life, warranting further research.

More Related Videos

Cell-based Therapy for Heart Failure in Rat: Double Thoracotomy for Myocardial Infarction and Epicardial Implantation of Cells and Biomatrix
09:11

Cell-based Therapy for Heart Failure in Rat: Double Thoracotomy for Myocardial Infarction and Epicardial Implantation of Cells and Biomatrix

Published on: September 22, 2014

12.5K
An In Vivo Estrogen Deficiency Mouse Model for Screening Exogenous Estrogen Treatments of Cardiovascular Dysfunction After Menopause
06:18

An In Vivo Estrogen Deficiency Mouse Model for Screening Exogenous Estrogen Treatments of Cardiovascular Dysfunction After Menopause

Published on: August 13, 2019

13.1K

Related Experiment Videos

Last Updated: Apr 15, 2026

Implantation of the Syncardia Total Artificial Heart
16:11

Implantation of the Syncardia Total Artificial Heart

Published on: July 18, 2014

36.3K
Cell-based Therapy for Heart Failure in Rat: Double Thoracotomy for Myocardial Infarction and Epicardial Implantation of Cells and Biomatrix
09:11

Cell-based Therapy for Heart Failure in Rat: Double Thoracotomy for Myocardial Infarction and Epicardial Implantation of Cells and Biomatrix

Published on: September 22, 2014

12.5K
An In Vivo Estrogen Deficiency Mouse Model for Screening Exogenous Estrogen Treatments of Cardiovascular Dysfunction After Menopause
06:18

An In Vivo Estrogen Deficiency Mouse Model for Screening Exogenous Estrogen Treatments of Cardiovascular Dysfunction After Menopause

Published on: August 13, 2019

13.1K

Area of Science:

  • Cardiology
  • Endocrinology
  • Internal Medicine

Background:

  • Chronic heart failure (CHF) survival rates have stagnated despite medical advances, necessitating exploration of new therapeutic targets.
  • CHF is characterized by neurohormonal activation and a significant reduction in anabolic drive, impacting function and prognosis.

Purpose of the Study:

  • To review the potential of hormone replacement therapy (HRT) in treating anabolic deficiencies associated with CHF.
  • To explore HRT as a novel therapeutic strategy for CHF patients with coexisting hormone deficiencies.

Main Methods:

  • Review of current scientific literature on CHF pathophysiology and HRT.
  • Analysis of evidence supporting the role of anabolic drive in CHF.
  • Hypothesis formulation for HRT application in a subset of CHF patients.

Main Results:

  • Evidence suggests CHF involves reduced anabolic drive, which has functional and prognostic implications.
  • Preliminary findings indicate potential benefits of HRT in CHF patients, possibly slowing disease progression.
  • HRT may be beneficial for CHF patients with coexisting hormone deficiencies.

Conclusions:

  • Hormone replacement therapy (HRT) is a theoretical treatment option for chronic heart failure (CHF).
  • HRT may enhance left ventricular structure, function, physical capacity, and quality of life in CHF patients.
  • Larger randomized controlled trials are required to validate the efficacy of HRT in CHF.